SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899909.
  • 2
    America Society of Clinical oncology. Special article: clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol. 1997; 15: 29963018.
  • 3
    Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol. 1999; 17: 35223530.
  • 4
    Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997; 15: 297303.
  • 5
    Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997; 15: 744749.
  • 6
    Steward W, Dunlop D, Cameron D, et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small-cell lung cancer [abstract]. Proc Am Clin Oncol. 1995; 14: 351.
  • 7
    Anton A, Diaz-Fernandez N, Gonzalez Larriba JL, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 1998; 22: 139148.
  • 8
    Sandler AB, Ansari R, McClean J, et al. Gemcitabine plus cisplatin in non-small-cell lung cancer: a phase II study. Eur J Cancer. 1995; 31a (Suppl 5): S225.
  • 9
    Sheperd F, Cormier Y, Burkes R, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer (NSCLC). Semin Oncol. 1997; 24 (Suppl 8): 2730.
  • 10
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 11
    Sheperd FA, Abratt R, Crino L, et al. The influence of gemcitabine and cisplatin on response and survival in advanced non-small-cell lung cancer. Lung Cancer. 2000; 30: 11725.
  • 12
    Grunewald R, Kantarjan H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycitidine (gemcitabine) administration in leukemia. Cancer Res. 1990; 50: 68236826.
  • 13
    Tempero M, Plunkett W, Ruizvan Haperen V, et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs. Fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol. 1999; 18: 273a.
  • 14
    Simon R, Wittes RE, Ellenberg SS. Randomised phase II clinical trials. Cancer Treat Rep. 1985; 69: 13751381.
  • 15
    World Health Organization. Handbook for reporting results of cancer treatment. Pub. no. 48. Geneva: World Health Organization, 1979.
  • 16
    Poplin E, Benson A III, Musanti R, et al. Pilot study of gemcitabine (10 mg/m2 per min) and cisplatin. Cancer Chemoter Pharmacol. 2002; 50: 8083.
  • 17
    Rinaldi M, Crinò L, Scagliotti GV, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol. 2000; 11: 12951300.
  • 18
    Ricci S, Antonuzzo A, Galli L, et al. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced non-small-cell lung carcinoma. Cancer. 2000; 89: 17141719.
  • 19
    Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol. 1996; (Suppl 10): 2531.